Büky B, Dévai G, Várady E, Rózsavölgyi A, Kovách I, Kovács A, Jancsó G, Waldinger K, Görgényi A, Zsolnai B
Second Department of Obstetrics and Gynecology, Semmelweis Medical University, Budapest, Hungary.
Acta Paediatr Hung. 1990;30(3-4):351-65.
We investigated the clinical efficacy of a new surfactant product, Curosurf, isolated from porcine lungs by liquid-gel chromatography. Ten premature newborn infants (birth weight 850-1850 g), all ventilated artificially for severe hyaline membrane disease categorized radiologically as stage III-IV, received a single dose of Curosurf (200 mg/kg) via the tracheal tube. This treatment resulted in a rapid improvement of oxygenation, similar to that observed by other teams collaborating in the study and, in an astonishingly fast resolution of the radiological changes. In comparison with a control group of 8 infants, the surfactant-treated babies also had a lower incidence of acute and chronic complications.
我们研究了一种通过液-凝胶色谱法从猪肺中分离出的新型表面活性剂产品珂立苏（Curosurf）的临床疗效。10名早产新生儿（出生体重850 - 1850克），均因严重透明膜病接受人工通气，放射学分类为III - IV期，通过气管插管接受了单剂量的珂立苏（200毫克/千克）。这种治疗使氧合迅速改善，类似于参与该研究的其他团队所观察到的情况，并且放射学改变惊人地快速消退。与8名婴儿的对照组相比，接受表面活性剂治疗的婴儿急性和慢性并发症的发生率也较低。
